Study #2022-0395
Early assessment of Ovarian cancer aggressiveness by metabolic imaging
MD Anderson Study Status
Enrolling
Treatment Agent
Hyperpolarized 13-C-pyruvate
Description
To learn if an MRSI can be performed on a 3T scanner using an investigational contrast drug called hyperpolarized 13-C pyruvate. 3T refers to the "strength" of the MRI machine.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Ovarian Cancer
Study phase:
Phase I
Physician name:
Priya Bhosale
Department:
Abdominal Imaging Department
For general questions about clinical trials:
1-877-582-0066
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.